Loading...
Loading...
BCLI| Name | Value |
|---|---|
| Revenues | 343.0K |
| Cost of Revenue | 66.0K |
| Gross Profit | 277.0K |
| Operating Expense | 4,738.0K |
| Operating I/L | -4,804.0K |
| Other Income/Expense | -774.0K |
| Interest Income | 538.0K |
| Pretax | -5,578.0K |
| Income Tax Expense | 4,966.0K |
| Net Income/Loss | -5,578.0K |
Brainstorm Cell Therapeutics Inc. is a biotechnology company specializing in the development and commercialization of autologous cellular therapies for neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform utilizes cell culture methods to induce bone marrow-derived mesenchymal stem cells to secrete neurotrophic factors, modulate disease processes, promote neuronal survival, and enhance neurological function. Brainstorm is advancing NurOwn through clinical trials for amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative conditions. The company generates revenue through the development and potential commercialization of its cellular therapy products, with a manufacturing partnership with Catalent.
